stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) Return on equity
BioMarin Pharmaceutical Inc.'s return on equity over the twelve months to 30 September 2026 was −0.31%, down 6.2 percentage points from fiscal 2025 (5.94%). Over the past ten years it has ranged from −24.4% (fiscal 2016) to 23.6% (fiscal 2020); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 5.94% | (2.11) |
| FY2024 | 8.05% | 4.54 |
| FY2023 | 3.51% | 0.32 |
| FY2022 | 3.19% | 4.72 |
| FY2021 | −1.53% | (25.16) |
| FY2020 | 23.6% | 24.41 |
| FY2019 | −0.78% | 1.89 |
| FY2018 | −2.67% | 1.53 |
| FY2017 | −4.20% | 20.19 |
| FY2016 | −24.4% | (15.64) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IBRX ImmunityBio, Inc. compare | 122.9% |
| TGTX TG Therapeutics, Inc. compare | 100.3% |
| TECH Bio-Techne Corp compare | 9.03% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| BMRN BioMarin Pharmaceutical Inc. | −0.31% |
| KYMR Kymera Therapeutics, Inc. compare | −27.3% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| PCVX Vaxcyte, Inc. compare | −36.5% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement